Compare Hut 8 Corp (HUT) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Illumina, Inc. — how do they compare? Hut 8 Corp trades at $108.8 (market cap $11.36B), while Illumina, Inc. trades at $190.08 (market cap $27.94B). The key difference: Illumina, Inc. is far larger — about 2.5× Hut 8 Corp's market cap, and Illumina, Inc. is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| HUT | ILMN | |
|---|---|---|
Market Cap | $11.36B | $27.94B |
Sector | Technology | Health |
52-Week High | $133.02 | $194.33 |
52-Week Low | $19.45 | $91.00 |
Enterprise Value | $11.63B | $29.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $100.93, up 10.37% in the past 24 hours, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, though it beat EPS estimates in two of the last three quarters. Recent news highlights its pivot to AI infrastructure, including a $4.25 billion bond issuance for data center projects (PRNewsWire, 2026-06-09).
Analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent losses pose risks. The stock's outlook hinges on successful execution of its digital infrastructure strategy, though cash flow challenges and competitive pressures remain key concerns for investors.
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
